29 related articles for article (PubMed ID: 7799020)
1. Therapeutic drug monitoring of etoposide in a 14-day infusion for non-small-cell lung cancer.
Ando Y; Minami H; Saka H; Ando M; Sakai S; Shimokata K
Jpn J Cancer Res; 1996 Feb; 87(2):200-5. PubMed ID: 8609070
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamic modeling of adverse effects of anti-cancer drug treatment.
de Vries Schultink AH; Suleiman AA; Schellens JH; Beijnen JH; Huitema AD
Eur J Clin Pharmacol; 2016 Jun; 72(6):645-53. PubMed ID: 26915815
[TBL] [Abstract][Full Text] [Related]
3. Etoposide induces cell death via mitochondrial-dependent actions of p53.
Jamil S; Lam I; Majd M; Tsai SH; Duronio V
Cancer Cell Int; 2015; 15():79. PubMed ID: 26251638
[TBL] [Abstract][Full Text] [Related]
4. Oral treatment with etoposide in small cell lung cancer - dilemmas and solutions.
Rezonja R; Knez L; Cufer T; Mrhar A
Radiol Oncol; 2013 Mar; 47(1):1-13. PubMed ID: 23450046
[TBL] [Abstract][Full Text] [Related]
5. Cytotoxic drug sensitivity of Epstein-Barr virus transformed lymphoblastoid B-cells.
Markasz L; Stuber G; Flaberg E; Jernberg AG; Eksborg S; Olah E; Skribek H; Szekely L
BMC Cancer; 2006 Nov; 6():265. PubMed ID: 17101045
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic optimisation of treatment with oral etoposide.
Toffoli G; Corona G; Basso B; Boiocchi M
Clin Pharmacokinet; 2004; 43(7):441-66. PubMed ID: 15139794
[TBL] [Abstract][Full Text] [Related]
7. Mechanistic models for myelosuppression.
Friberg LE; Karlsson MO
Invest New Drugs; 2003 May; 21(2):183-94. PubMed ID: 12889739
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamic modeling of the entire time course of leukopenia after a 3-hour infusion of paclitaxel.
Minami H; Sasaki Y; Watanabe T; Ogawa M
Jpn J Cancer Res; 2001 Feb; 92(2):231-8. PubMed ID: 11223553
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic drug monitoring in 21-day oral etoposide treatment for lung cancer.
Ando Y; Minami H; Saka H; Ando M; Sakai S; Shimokata K
Jpn J Cancer Res; 1996 Aug; 87(8):856-61. PubMed ID: 8797893
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of prolonged oral therapy with etoposide (VP16) for patients with recurrent malignant glioma.
Fulton D; Urtasun R; Forsyth P
J Neurooncol; 1996 Feb; 27(2):149-55. PubMed ID: 8699237
[TBL] [Abstract][Full Text] [Related]
11. Predictive performance of a pharmacodynamic model for oral etoposide.
Miller AA; Tolley EA
Cancer Res; 1994 Apr; 54(8):2080-3. PubMed ID: 8174108
[TBL] [Abstract][Full Text] [Related]
12. Prolonged administration of oral etoposide in non-small-cell lung cancer: a phase II trial.
Waits TM; Johnson DH; Hainsworth JD; Hande KR; Thomas M; Greco FA
J Clin Oncol; 1992 Feb; 10(2):292-6. PubMed ID: 1310104
[TBL] [Abstract][Full Text] [Related]
13. [Prolonged oral etoposide therapy in advanced stage lung cancer].
Bozóky G; Ruby E; Góhér I; Mohos A; Lengyel M
Orv Hetil; 1997 Jul; 138(28):1791-5. PubMed ID: 9280873
[TBL] [Abstract][Full Text] [Related]
14. The role of hematopoietic growth factors in support of ifosfamide/carboplatin/etoposide chemotherapy.
Crawford J; George M
Semin Oncol; 1995 Jun; 22(3 Suppl 7):18-22. PubMed ID: 7541916
[TBL] [Abstract][Full Text] [Related]
15. Clinical and pharmacologic analysis of hyperfractionated daily oral etoposide.
Minami H; Ando Y; Sakai S; Shimokata K
J Clin Oncol; 1995 Jan; 13(1):191-9. PubMed ID: 7799020
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic drug monitoring of 21-day oral etoposide in patients with advanced non-small cell lung cancer.
Miller AA; Tolley EA; Niell HB
Clin Cancer Res; 1998 Jul; 4(7):1705-10. PubMed ID: 9676845
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
